BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verdam FJ, Rensen SS, Driessen A, Greve JW, Buurman WA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol. 2011;45:149-152. [PMID: 20661154 DOI: 10.1097/mcg.0b013e3181e12c24] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Plaza-Diaz J, Gomez-Llorente C, Abadia-Molina F, Saez-Lara MJ, Campaña-Martin L, Muñoz-Quezada S, Romero F, Gil A, Fontana L. Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats. PLoS One 2014;9:e98401. [PMID: 24852284 DOI: 10.1371/journal.pone.0098401] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
2 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
3 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
4 du Plessis J, Korf H, van Pelt J, Windmolders P, Vander Elst I, Verrijken A, Hubens G, Van Gaal L, Cassiman D, Nevens F, Francque S, van der Merwe S. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. PLoS One 2016;11:e0166048. [PMID: 27992443 DOI: 10.1371/journal.pone.0166048] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
5 Adar T, Ben Ya’acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M, Wong V, Muller B, Rawlin G, Ilan Y. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol. 2012;167:252-260. [PMID: 22236001 DOI: 10.1111/j.1365-2249.2011.04511.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
6 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Nien HC, Hsu SJ, Su TH, Yang PJ, Sheu JC, Wang JT, Chow LP, Chen CL, Kao JH, Yang WS. High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments. PLoS One 2017;12:e0170028. [PMID: 28107471 DOI: 10.1371/journal.pone.0170028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Segers FM, Verdam FJ, de Jonge C, Boonen B, Driessen A, Shiri-Sverdlov R, Bouvy ND, Greve JW, Buurman WA, Rensen SS. Complement alternative pathway activation in human nonalcoholic steatohepatitis. PLoS One 2014;9:e110053. [PMID: 25299043 DOI: 10.1371/journal.pone.0110053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
9 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
10 Petrasek J, Csak T, Ganz M, Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013;28 Suppl 1:93-8. [PMID: 23855302 DOI: 10.1111/jgh.12020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
11 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
12 Zhou X, Han D, Xu R, Wu H, Qu C, Wang F, Wang X, Zhao Y. Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats. Oncotarget 2016;7:80223-37. [PMID: 27784003 DOI: 10.18632/oncotarget.12831] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
13 Park JS, Seo JH, Youn HS. Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16:22-27. [PMID: 24010102 DOI: 10.5223/pghn.2013.16.1.22] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
14 Wattacheril J, Rose KL, Hill S, Lanciault C, Murray CR, Washington K, Williams B, English W, Spann M, Clements R, Abumrad N, Flynn CR. Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res 2017;47:1469-83. [PMID: 28258704 DOI: 10.1111/hepr.12885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
15 Fedirko V, Tran HQ, Gewirtz AT, Stepien M, Trichopoulou A, Aleksandrova K, Olsen A, Tjønneland A, Overvad K, Carbonnel F, Boutron-Ruault MC, Severi G, Kühn T, Kaaks R, Boeing H, Bamia C, Lagiou P, Grioni S, Panico S, Palli D, Tumino R, Naccarati A, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Castaño JM, Barricarte A, Sánchez MJ, Dorronsoro M, Quirós JR, Agudo A, Sjöberg K, Ohlsson B, Hemmingsson O, Werner M, Bradbury KE, Khaw KT, Wareham N, Tsilidis KK, Aune D, Scalbert A, Romieu I, Riboli E, Jenab M. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med 2017;15:72. [PMID: 28372583 DOI: 10.1186/s12916-017-0830-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
16 Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Chung SJ, Yang SY, Kim JS. Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2016;2016:7653689. [PMID: 28070183 DOI: 10.1155/2016/7653689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
18 Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013;8:e62885. [PMID: 23638162 DOI: 10.1371/journal.pone.0062885] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 18.4] [Reference Citation Analysis]
19 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 339] [Article Influence: 60.3] [Reference Citation Analysis]
20 Okubo H, Kushiyama A, Nakatsu Y, Yamamotoya T, Matsunaga Y, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Asano T. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci 2018;19:E3064. [PMID: 30297626 DOI: 10.3390/ijms19103064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 79] [Article Influence: 11.5] [Reference Citation Analysis]
22 Kitabatake H, Tanaka N, Fujimori N, Komatsu M, Okubo A, Kakegawa K, Kimura T, Sugiura A, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Koinuma M, Sano K, Aoyama T, Tanaka E. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(4): 712-722 [PMID: 28216979 DOI: 10.3748/wjg.v23.i4.712] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
23 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
24 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
27 Jensen ET, Bertoni AG, Crago OL, Hoffman KL, Wood AC, Arzumanyan Z, Lam LK, Roll K, Sandow K, Wu M, Rich SS, Rotter JI, Chen YI, Petrosino JF, Goodarzi MO. Rationale, design and baseline characteristics of the Microbiome and Insulin Longitudinal Evaluation Study (MILES). Diabetes Obes Metab 2020;22:1976-84. [PMID: 32687239 DOI: 10.1111/dom.14145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Jin R, Willment A, Patel SS, Sun X, Song M, Mannery YO, Kosters A, McClain CJ, Vos MB. Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. Int J Hepatol. 2014;2014:560620. [PMID: 25328713 DOI: 10.1155/2014/560620] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
29 Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J Gastroenterol 2014; 20(42): 15632-15649 [PMID: 25400447 DOI: 10.3748/wjg.v20.i42.15632] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
30 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
31 Ahmed O, Robinson MW, O'Farrelly C. Inflammatory processes in the liver: divergent roles in homeostasis and pathology. Cell Mol Immunol 2021;18:1375-86. [PMID: 33864004 DOI: 10.1038/s41423-021-00639-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fukuda S, Ohno H. Gut microbiome and metabolic diseases. Semin Immunopathol. 2014;36:103-114. [PMID: 24196453 DOI: 10.1007/s00281-013-0399-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 9.7] [Reference Citation Analysis]
33 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]